126 results
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
8 May 24
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for
4:41pm
statements, including those relating to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product … candidates, including CX-904, CX-2051, and CX-801, the potential benefits or applications of CytomX’s PROBODY® therapeutic platform, CytomX’s or its
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
11 Mar 24
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
4:02pm
to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product candidates, including CX-2051, CX … -801, and CX-904, the potential benefits or applications of CytomX’s PROBODY® therapeutic platform, CytomX’s or its collaborative partners’ ability
8-K
EX-99.1
h4esdm
7 Nov 23
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:05pm
424B3
8i19o
25 Aug 23
Prospectus supplement
5:36pm
8-K
EX-99.1
ouel59 w0gumor7
8 Aug 23
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-10.1
k3g7th3ow
30 Jun 23
Entry into a Material Definitive Agreement
7:07pm
8-K
EX-99.1
jo8gkc0fcs8ov cax814
9 May 23
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:12pm